ctDNA Testing Can Guide Adjuvant Treatment in dMMR Solid Tumors
Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.
Related Articles
CT Scans May Cause as Many as 5% of Cancers Diagnosed Each Year in the US
The most common projected cancers in adults were lung cancer, colon cancer, leukemia, bladder cancer, and stomach cancer.
Childhood Cancer Survivors Have Higher Risk of Chronic Conditions, Early Death – Oncology Nurse Advisor
Childhood cancer survivors “may experience considerable accelerated aging throughout their lifespan,” the researchers wrote.
Using Liquid and Tissue Biopsy Results to Guide Treatment May Provide Benefits
Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.
Opinion: Chemo-Free Regimens Join Crowded Field of Potential Therapies for Osimertinib-Resistant NSCLC
Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.
ctDNA Assay Can Detect Colorectal Cancer Recurrence Months Before Imaging
New research suggests that a ctDNA assay can detect colorectal cancer recurrence months before it is detected via imaging.
The Grand Roundup
We are introducing a new way to deliver the most relevant information you need for your patients on the topics that matter most to your…
Several Factors May Predict PFS, OS After ICI Discontinuation
“These results may help guide management strategies and prognostication among patients with advanced NSCLC who experience severe irAE and in whom permanent ICI discontinuation is…
Which CDK4/6 Inhibitor Has the Greatest Risk of Cardiotoxicity?
The estimated incidence of hypertension was highest among patients receiving ribociclib.
Zongertinib Confers Benefit in HER2-Mutant NSCLC
Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.
Dostarlimab May Eliminate Need for Surgery in Patients With dMMR Solid Tumors
Dostarlimab may eliminate the need for surgery in certain patients with dMMR solid tumor malignancies, a phase 2 study suggests.